title: Antiviral therapy for chronic hepatitis C in 2014.
abstract: An all-oral therapy for treating hepatitis C (HCV) is now available for the most common genotypes although interferon-based therapy is still recommended for interferon-eligible patients with HCV genotype 1. For most patients, a prior history of treatment or presence of cirrhosis does not appear to significantly impact eradication rates with direct acting antivirals (DAA). The promising results from the numerous clinical trials of DAA's for HCV together with their tolerability represent a tremendous advance in our management of this disease, particularly as treatment is often well-tolerated, associated with few side effects and significantly shortened in duration. We will review several of the peer-reviewed landmark studies of DAA's for the treatment HCV and conclude with an expert commentary and five year view.
authors.affiliation: Creighton University Medical Center, 601 North 30th Street, Omaha, NE 68131, USA.
authors.forename: Manogna
authors.initials: M
authors.lastname: Nookathota
authors.forename: Sandeep
authors.initials: S
authors.lastname: Mukherjee
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic
chemical_list: D000998:Antiviral Agents
keywords: Q80K polymorphism; direct-acting antivirals; hepatitis C; pangenotypic; polymerase inhibitors; protease inhibitors